Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
August 2018 Vol 11, Special Issue
Conference Highlights ASCO
Precision Medicine and Immunotherapy Highlighted at ASCO 2018
Wayne Kuznar
Read More
Emerging Therapies
Ivosidenib a New Standard of Care for Relapsed or Refractory AML with IDH1 Mutation
Phoebe Starr
Read More
Emerging Therapies
LOXO-292 Highly Effective in RET-Positive Cancers
Chase Doyle
Read More
FDA Approvals
FDA Approvals, News & Updates - August 2018
Read More
Cell-Free DNA Assays Could Result in a New Blood Test for Early Detection of Cancer
Wayne Kuznar
Read More
Immunotherapy
Investigational CAR T-Cell Therapy, bb2121, Shows Durable Responses in Relapsed or Refractory Multiple Myeloma
Wayne Kuznar
Read More
Immunotherapy
Immunotherapy Combinations "Raising the Bar"
Phoebe Starr
Read More
Breast Cancer
Less Is More: 6 Months of Trastuzumab Treatment Equivalent to 12 Months in HER2-Positive Breast Cancer
Phoebe Starr
Read More
Breast Cancer
First-in-Class Antibody-Drug Conjugate Effective in HER2-Negative Metastatic Breast Cancer
Chase Doyle
Read More
IMPACT: Matching Treatment and Molecular Testing Extends Survival in Advanced Cancer
Wayne Kuznar
Read More
1
2
3
Page 2 of 3
Results 11 - 20 of 24